Covidien Appoints New Leader for Vascular Therapies Business

Covidien plc has appointed Stacy Enxing Seng as president of the company’s Vascular Therapies Global Business Unit. She will report directly to Peter L. Wehrly, senior vice president and group president, Respiratory & Monitoring Solutions and Vascular Therapies.

Enxing Seng, 47, will manage a global organization of 4,000 employees with $1.4 billion in revenue. She joined Ireland-based Covidien in July 2010 through the acquisition of ev3 Inc., where she was a founding member and executive officer responsible for leading the Plymouth, Minn.-based firm’s Peripheral Vascular Division from inception to a $350 million business.

“Stacy has a proven track record in leading and growing businesses,” said Wehrly. “Her experience at ev3, focus on the customer and the employee, combined with her strong knowledge of the vascular market makes her the ideal candidate to lead our Vascular business.”

Before she joined ev3, Stacy held various positions of increasing responsibility for Boston Scientific Corp., SCIMED Life Systems Inc., Baxter Healthcare and American Hospital Supply. She received an MBA from Harvard University and a bachelor’s degree from Michigan State University.